Forte BioSciences Inc(FBRX) 2023Q1 Earnings Summary
Bullish Points: 1. Forte BioSciences Inc (FBRX) had cash and cash equivalents of approximately $35.9 million as of March 31, 2023, which is expected to fund its operations for at least 12 months from the filing date of this Form 10-Q. 2. The company is focused on developing its FB-102 program for autoimmune diseases, which is currently in preclinical development. 3. Forte BioSciences is a biopharmaceutical company focused on developing its product candidate, FB-102, for autoimmune applications in graft-versus-host disease, vitiligo, and alopecia areata. 4. Forte filed a shelf registration statement on Form S-3 in June 2021, allowing it to raise up to $300 million in additional capital. 5. Forte entered into an ATM Facility on March 31, 2022, to offer and sell shares of its common stock up
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.